| 摘要 |
<p>The present invention provides a liquid aqueous formulation for the intranasal administration of apomorphine, which comprises:
(a) at least about 15 mg/ml of apomorphine; and
(b) a solubilising agent selected from
(i) at least one polyoxyethylene-polyoxypropylene copolymer (poloxamer);
(ii) at least one cyclodextrin; and
(iii)
at least one cyclodextrin together with chitosan. The formulations of the invention can be used in the treatment/management of Parkinson's disease.</p> |
